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ABSTRACT
Aim To report long-term outcomes on best-corrected
visual acuity (BCVA) and treatment intervals with a treat-
and-extend (T&E) regimen in patients with neovascular
age-related macular degeneration (nAMD).
Methods This observational study included treatment-
naïve patients with nAMD, treated with aflibercept.
A specific T&E protocol without a loading phase and
predefined exit criteria was administered. After reaching
predefined ‘exit-criteria’, the treatment period was
complete, and patients were observed three monthly.
Results Eighty-two patients with a follow-up period of
≥2 years were included. BCVA (mean±SD, ETDRS letters)
increased from 51.9±25.2 at baseline to 63.7±17.7
(p<0.0001) at 1 year, 61.7±18.5 (p<0.0001) at 2 years,
62.4±19.5 (p<0.0001, n=61) at 3 years and remained
insignificantly higher than baseline at 4 years at 58.5
±24.3 (p=0.22). Central subfield thickness (mean±SD,
μm) decreased significantly from 387.5±107.6
(p<0.0001) at baseline to 291.9±65.5 (p<0.0001) at
1 year, and remained significantly lower until 4 years at
289.0±59.4 (p<0.0001). Treatment intervals (mean±SD,
weeks) could be extended up to 9.3±3.1 weeks at 1 year
and remained at 11.2±3.5 weeks at 4 years. Twenty-nine
(35%) patients reached exit criteria and continued with
three monthly observation only.
Conclusions After 4 years of treatment, initial vision gains
were maintained with a reasonable treatment burden, even
without an initial loading phase. Our results on functional
outcomes are comparable with large controlled studies.
INTRODUCTION
Intravitreal injections (IVTs) of anti-vascular
endothelial growth factor (VEGF) are important to
preserve visual acuity in patients with neovascular
age-related macular degeneration (nAMD). Large
studies have shown the benefits of frequent injec-
tions of anti-VEGFagents and the hereby- prevented
socioeconomic impacts, considering the highworld-
wide prevalence of nAMD.1–4 In spite of the excel-
lent therapeutic options, the associated regular
injections and visits represent a burden for the
often elderly and multimorbid patients.5 As
a reaction to the rigid treatment protocols of the
pivotal studies with long-term monthly injections,
individualised regimens are increasingly popular in
daily clinical practice.
In contrast to ‘pro re nata’ (PRN) protocols that
usually mandate monthly visits, ‘treat-and-extend’
(T&E) regimens include a disease activity evalua-
tion as well as an IVT of the anti-VEGF agent at
every visit. After a loading phase (either two or
three monthly injections), predefined stability cri-
teria, evaluated with optical coherence tomography
(OCT), and best-corrected visual acuity (BCVA)
ensure standardised extension of the visit intervals
and injections to up to 16 weeks, depending on
the specific regimens. While it is widely common
to use a loading dose of three monthly injections,
not all registries included a loading phase.6 7
Noninferiority of one versus three initial doses
was demonstrated in PRN settings.2 8 It has been
shown that T&E regimens require significantly
fewer clinical visits than PRN regimens.6 9–11 In
recent years, T&E protocols have increasingly
been used in patients with nAMD, and current
data on visual outcomes and injection intervals
have shown encouraging results.12–15 However,
most studies do not exceed beyond 12–14 weeks,
and evidence about treatment cessation is scarce.
Arendt et al pointed out the usefulness of prede-
fined ‘exit-criteria’, to prevent potential unneces-
sary lifelong treatment.16 More precisely, patients
who meet these stability criteria in three consecu-
tive 16 weekly visits can terminate injections.
Regular three monthly control visits allow timely
identification of potential recurrence, when treat-
ment should be resumed. Since T&E regimens are
relatively new in clinical use, reports about long-
term outcomes are scarce, and the debate about
the ideal treatment protocol is still ongoing.
In our study, we report functional and anatomical
4-year outcomes from our specific T&E regimen
with exit-strategy in patients treated with afliber-
cept for choroidal neovascularisation (CNV), sec-
ondary to age-related macular degeneration.
METHODS
This was a single-centre retrospective observa-
tional study conducted at the Department of
Ophthalmology at the University Hospital in
Bern, Switzerland and included patients first pre-
senting between April 2014 and March 2016.
Patients with treatment-naïve, newly diagnosed
nAMDwith CNVand associated visual impairment
without restriction of lesion size were included
(table 1). Active nAMD lesions were defined as
lesions with either subretinal fluid (SRF) and/or
intraretinal fluid (IRF). All patients were started
on a T&E protocol for intravitreal treatment with
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aflibercept (EYLEA, Regeneron, Tarrytown, NY, USA). The
study was approved by the local ethics committee (KEK No.
093/13) and was conducted in accordance with the
International Conference on Harmonisation—Good Clinical
Practice guidelines and in compliance with the Declaration of
Helsinki. None of the patients had previous injections with anti-
VEGF agents. If both eyes were affected, the first diagnosed eye
was included in the study. Unless clinical diagnosis of nAMDwas
obvious, the diagnosis was confirmed by fluorescein angiogra-
phy. Open inclusion criteria ensured best possible real-life
representation. Patients were excluded if the main visual impair-
ment was not caused by nAMD. These conditions included
significant fibrosis, geographic atrophy, late-stage or uncon-
trolled glaucoma, retinal detachment, visually significant catar-
act, aphakia, vitreous haemorrhage, proliferative diabetic
retinopathy or CNV of any cause other than nAMD. We
excluded patients who did not adhere to the treatment schedule,
namely if injections were behind schedule >2 weeks, or if BCVA
or OCTexamination was not possible repeatedly due to incom-
pliance or physical or cognitive incapability.
T&E regimen
An outline of our Bern T&E protocol has been published pre-
viously and is shown in figure 1. Briefly, patients underwent
ETDRS visual acuity testing and spectral-domain OCT
(Heidelberg Engineering, Heidelberg, Germany) imaging includ-
ing central subfield thickness (CST)measurement, followed by an
IVT of 2 mg aflibercept at each visit. The second injection was
administered 4 weeks after the initial treatment. Direct extension
of the injection interval by 2 weeks was possible thereafter, if
predefined stability criteria were reached. Two independent sta-
bility criteria were defined (at least one required): (1) no evidence
of any IRF or SRF or sub-retinal pigment epithelium (RPE) fluid
in theOCTand (2) SRF<50 μm and/or present sub-RPE fluid, no
IRF, AND no change in SRF and sub-RPE fluid with stable BCVA
at the third consecutive visit. Treatment intervals were extended
until the maximal extension interval of 16 weeks was reachedOR
stability criteria were no longer fulfilled. Treatment intervals
were then shortened by 1 week until stability was reached
again. Once stability was reached again, the treatment interval
was kept unchanged for the next 6 months. If the patients met the
stability criteria at three consecutive visits of 16-week intervals,
the ‘exit-criteria’ were met, and the patients terminated the ther-
apy. In the best possible scenario, patients needed 10 injections
before treatment completion. Clinical visits without injections
ensured disease control after therapy termination. If at any time
patients showed signs of recurrent disease, the T&E protocol was
resumed from the beginning.
Statistical analysis
Visual acuity data failed commonly used normality tests (Shapiro-
Wilk, D’Agostino-Pearson, Anderson-Darling and Kolmogorov-
Smirnov). Therefore, the non-parametric Wilcoxon signed-rank
test was used analyse BCVA, CST and treatment interval differ-
ences as previously in a similar setting.15 We applied the last-visit-
carried-forward principle for missed visits, and patients lost to
follow-up were analysed up to the time of dropout and then
excluded from statistical analysis. Patients were followed up after
cessation of therapy (patients in remission), and their visual acuity
and CST data are included in the statistics. Data are presented as
the mean±SD, and p<0.05 values were considered statistically
significant.
RESULTS
Of the 131 patients with newly diagnosed nAMD, 82 (46 female)
were followed up for at least 2 years and included in the study
(figure 2). At baseline, the mean age was 81.6±8.8 years (range,
59–97) and 36 (44%) patients were pseudophakic. Table 1 illus-
trates the demographics and baseline characteristics. The mean
duration of the follow-up period amounted to 3.5±0.65 (mean
±SD) years, while the mean number of injections of the patients
who completed at least 2 years of therapy was 19.2±9.0 (n=82,
mean±SD). Sixty-one patients had a follow-up period of at least 3
years, and 50 patients of 4 years.
The mean BCVA increased from 51.9±25.2 (mean±SD, med-
ian: 60) letters at baseline to 63.7±17.7 letters (+11.8, p<0.0001,
median: 68) at 1 year, 61.7±18.5 letters (+9.8, p<0.0001, med-
ian: 65) at 2 years, 62.4±19.5 (+10.5, p<0.0001, median: 68) at
3 years, and 58.5±24.3 (+6.6, p=0.22, median: 65) letters at 4
years, as shown in figure 3.
The mean CST decreased significantly from 387.5±107.6 μm
(mean±SD) at baseline to 291.9±65.5 μm (−95.6, p<0.0001) at
1 year, and remained significantly lower until 4 years at 289.0
±59.4 μm (−98.5, p<0.0001), as shown in figure 4.
Figure 1 Outline of the Bern treat-and-extend regimen. (A) Treatment
algorithm: 4 weeks after the first injection, disease activity evaluation
and a second injection take place. In case of stability, extension of the
intervals by 2 weeks is triggered. If stability criteria are not fulfilled,
a repeat injection takes place 4 weeks later. If patients show signs of
active disease at any time, the intervals are shortened by 1 week
(asterisk), until disease stability is reached. After shortening of the
interval, extension is not possible for the following 6 months. (B) Outline
of the best-case scenario with the minimal number of 10 injections in 2
years. nAMD, neovascular age-related macular degeneration.
Table 1 Demographics and baseline characteristics
Number of patients 82
Age (years, mean±SD) 81.6 ±8.8
Female/Male 46 (56%)/36 (44%)
Visual acuity (ETDRS letters, mean±SD) 51.9 ±25.2
Central subfield thickness (μm, mean±SD) 387.5 ±107.6
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Treatment intervals started at 4 weeks and were extended up to
9.3±3.1 weeks (mean±SD) after 1 year, 12.7±4.2 weeks after 2
years, 11.9±3.9 weeks after 3 years and remained stable at 11.2
±3.5 weeks after 4 years, as shown in figure 5. Fifty per cent of
the patients reached a median treatment interval of at least
10 weeks (5.2 injections per year). After 2 years, the interval
was extended up to a median of 14.0 weeks (3.7 injections
per year, n=82). After 3 years, the median interval decreased to
12.6 weeks (4.1 injections per year, n=43), and ended at
11.0 weeks (4.7 injections per year, n=32) after 4 years of treat-
ment. The mean total number of injections for patients under
treatment amounted to 8.1±2.0 (n=82) after the first, 13.2±4.1
(n=82) after the second, 19.4±6.6 (n=43) after the third and
24.9±6.8 (n=32) after the fourth year of treatment. The mean
number of injections per year amounted to 8.1±2.0 injections
(n=82) in the first, 5.5±2.5 injections (n=82) in the second, 4.8
±2.5 injections (n=43) in the third and 5.0±1.6 injections
(n=32) in the fourth year.
Direct extension without loading phase was possible in 42
(51%) of the patients. Two (5%) of these patients had an immedi-
ate relapse after initial extension.
Out of the included 82 patients, 29 (35%) reached the ‘exit-
criteria’ and terminated the therapy after 2.6±0.55 (mean±SD)
years. Twelve (15%) patients reached the exit-criteria after the
minimal number of no more than 10 injections and were consid-
ered ‘rapid responders’, whereas 10 and 7 patients reached the
exit-criteria in the third and fourth year, respectively. Seventy
patients (85%) needed reduction of the treatment interval at
least once, or needed more time for the initial extension of the
intervals, due to disease activity. The rapid responders did not
show significant differences from the other patients in any
observed parameter. Visual acuity did not correlate to the injec-
tion intervals nor to the total number of injections at any time of
the observed period. Qualitative analyses of OCTcharacteristics
are shown in figure 6. At baseline, 47.5% of the patients showed
Figure 3 Visual acuity data of all patients (injections+exit) from
baseline until month 48. Values are displayed as mean±95% CI. BCVA,
best-corrected visual acuity.
Figure 4 Central macular subfield thickness data of all patients
(injections+exit) from baseline until month 48. Values are displayed as
mean±95% CI.
Figure 5 Interval between injections of patients under treatment from
baseline until month 48.
Figure 2 Flow diagram illustrating the number of patients in the study,
according to their treatment-status ‘exit’ or ‘injections’, total number and
lost to follow-up. Exit-patients suffering from recurrence went back to
injections (asterisk).
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only SRF, 35.4%presented only IRFand 17.1% had both IRFand
SRF. After 4 years, 72% of CNVs were inactive, 14.0% had only
SRF and 14.0% showed IRF.
Eight patients (28%) reaching the exit criteria suffered from
a recurrence in the observation period, and therapy was resumed
after 52.24±25.9weeks (mean±SD, range: 21.9–111.3). Eighteen
(62%) exit patients were followed without recurrence until year 4,
two patients went to private ophthalmologists and one died.
DISCUSSION
Our data documents stable visual acuity in most of our followed
patients, even after 4 years of follow-up. This finding is compar-
able to results from other recently published studies.15 17–20 We
observed a relatively low baseline vision of 51.9 letters, partially
explained by the fact that our clinic often treats patients after
referral from local ophthalmologists, and that our inclusion cri-
teria were relatively loose. The excellent mean BCVA gain of 11.8
letters after 2 years was maintained and resulted in a visual acuity
of 58.5 letters after 4 years, which is slightly lower than in the
VIEW 1 extension study (62.8 letters).19 Our findings are com-
parable to results from a recent study by Traine et al, conducted in
a similar population, where a BCVA gain of 6.0 letters at 2 years
and 3.6 letters at 4 years was reported.15 Gayadine-Harricham
et al observed a BCVA-improvement of 7.3 letters at 1 year and
6.2 letters at 4 years.21 Another study reported a BCVA gain of
6.6 at 3 years.22 In general, our data support the T&E protocol
with extension of the intervals as soon as disease stability is
documented. In summary, our visual acuity data are consistent
with expectations in this setting.
Our OCT data showed stable long-term CST and suggests
a constant proportion of fluid-free retina throughout years 1–4.
These findings are again consistent with previous studies.15 23
Furthermore, this supports the hypothesis that the slow decrease
in visual acuity from years 1 to 4 is mainly caused by the dry AMD
component and fibrosis, but not recurrent activity of the CNV.
Regarding injection frequency, our study results are compar-
able to the VIEW 1 extension study and the study from Traine
et al. An extension of the intervals beyond 14 weeks after 2 years
was possible in about 50% of the patients, 40% without recur-
rence. The option of treatment exit in our study should be con-
sidered as well, as it decreases the overall injection frequency
when compared to studies lacking this option.
The proportion of 29% of the patients fulfiling the exit-criteria
with an acceptable recurrence rate after therapy cessation in this
study supports the use of a predefined exit plan and suggests that
this T&E algorithmwith exit-strategy generates good results with
a reasonable treatment burden. It is of great importance to
observe patients closely after treatment cessation in order not to
miss recurrence. The safety of an exit option was affirmed by
a study of Adrean et al. Although a mean of 4 letter loss occurred
at recurrence, BCVA completely recovered after treatment was
resumed.24 The difference to the report of Arendt et al,16 who
reported an exit rate of 12%, might be explained by the fact that
this study only included therapy-naïve patients while the study by
Arendt et al also included previously treated patients with
nAMD. Supposedly, therapy termination should follow
a defined algorithm to ensure repeatability and comparability of
outcomes in long-term studies. Of note, a meta-analysis byOkada
et al on ranibizumab in patients with nAMD suggested super-
iority of T&E regimen relative to PRN treatment and reported
comparable outcomes to monthly dosing regimen.25
Our data furthermore support the usage of a T&E regimen
without a loading phase, since disease activity was only observed
in two patients after early extension.
This study, however, might be flawed by non-compliance and
selection bias. Patients who interrupt therapy in the first 2 years
andnever return to the clinicwould probably sufferworse outcomes
that are not accounted for in this analysis. In addition, such patients
have a higher risk of recurrence. Also, we cannot speculate about
exit patients whowere lost to follow-up. These patientsmight suffer
from undetected recurrence. Our high lost to follow-up rate has to
be considered when looking at our data. Finally, our results have to
be interpreted with caution because of the retrospective nature but
encourage the launch of larger prospective studies.
CONCLUSION
This ‘real-life’ report presents long-term results that are largely
consistent with prospective controlled multicenter trials and sup-
port the use of T&E regimens with exit-strategy but without
loading phase in patients with newly diagnosed nAMD.
A clearly defined exit-strategy is mandatory to ascertain standar-
dised treatment termination and consistent outcomes.
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Figure 6 Segregation of patients according to OCT findings (dry,
subretinal fluid, intraretinal fluid, and subretinal and intraretinal fluid) at
each year of follow-up. OCT, optical coherence tomography.
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